UPDATE: Jefferies Maintains Buy On Ardelyx, Raises Tgt To $11 After Co's 'positive topline data from the pivotal PHREEDOM study, where tenapanor treated pts saw mean decreases in serum phosphorus and an AE profile consistent with the initial ph 3 study'